YARDLEY, Pa.--(BUSINESS WIRE)--OptiNose today announced that the company will present at the 33rd annual J.P. Morgan Healthcare Conference. CEO Peter Miller will discuss the Company's recent milestones, pipeline and strategy for 2015.
“Our bi-directional Breath Powered technology has the potential to improve treatment for patients across a wide range of underserved disease states, as evidenced by the success we have seen to date in clinical trials for our OPN-375 product to treat chronic nasal inflammatory diseases,” Miller stated. “We look forward to providing the investment community an update on our business, including our strong pipeline and the products we will be focused on developing in 2015 and beyond.”
Miller will present on Monday, January 12, 2015 at 1:30 p.m. in the Elizabethan C/D room at the Westin St. Francis Hotel in San Francisco.
OptiNose is a Specialty Pharmaceutical Company developing a promising pipeline of late stage new products. The Company’s patented Bi-Directional™ Breath Powered™ technology platform creates differentiated treatments by enabling deep intranasal drug deposition. OptiNose successfully out-licensed a first product at the end of phase 3 (AVP-825 for Migraine, licensed to AVNR in North America), and has proven clinical success with other products, including OPN-375, a treatment for Chronic Nasal Inflammatory Diseases (CNID) that will soon complete Phase 3. OPN-375 has the potential to be a breakthrough that creates a new standard of care for the treatment of serious CNID, such as Chronic Sinusitis. Other OptiNose pipeline products also target large and attractive markets with significant unmet need, including nose-to-brain technology applications such as OPN-300 for Autism. OptiNose has corporate offices in the US, Norway and the UK. For more information, please visit www.optinose.com.
About OptiNose’s Bi-Directional™ Breath Powered™ Delivery Technology
OptiNose's patented closed-palate Bi-Directional Breath Powered delivery technology is unique in that it uses the natural function of a user’s breath to propel medications beyond the nasal valve into the deep, targeted areas of the nasal cavity more effectively and efficiently than current treatment approaches. A user exhales into the device, creating a natural closure of the soft palate and sealing off the nasal cavity completely. The exhaled breath carries medication from the device into one side of the nose through a specially shaped sealing nosepiece, balancing the pressure on the soft palate. Narrow nasal passages are gently expanded and medication is transported well beyond the nasal valve to targeted sites. After delivering medication to the targeted sites, air flows around to the opposite side of the nasal cavity and exits through the other side of the nose rather than into the throat or lungs.